UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 6, 2010
AMSTEM CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
| Nevada | 000-51931 | 88-0374180 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
13406 Racetrack Road #233, Tampa, FL 33626
(Address of principal executive offices – zip code)
(813) 283-2556
(Registrant’s telephone number, including area code)
(former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c)) |
| ITEM 2.02 | RESULTS OF OPERATIONS AND FINANCIAL CONDITION |
AmStem Corporation (AMST, or “the Company”), announced the financial results for its 90% owned subsidiary, Histostem, for the year ended December 31, 2009. A copy of the release is attached as Exhibit 99.1.
The information furnished herein, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.
| ITEM 7.01 | REGULATION FD DISCLOSURE |
AmStem Corporation (AMST, or “the Company”), announced the financial results for its 90% owned subsidiary, Histostem, for the year ended December 31, 2009. A copy of the release is attached as Exhibit 99.1.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
Exhibits
| 99.1 | Press release dated April 5, 2010. |
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AmStem Corporation | ||
| By: | /s/ Andrew J. Norstrud | |
| Name: |
Andrew J. Norstrud | |
| Title: |
Chief Financial Officer | |
Date: April 6, 2010